PC-003 · melanocortin · pt-141
PT-141
Bremelanotide
Also: Vyleesi
§ Overview
A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors (Viagra), PT-141 works through the central nervous system, affecting sexual desire rather than blood flow mechanics.
§ Mechanism
Activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, modulating neural pathways involved in sexual arousal and desire. Derived from Melanotan II but engineered specifically for sexual function.
§ Common Uses
- → Female sexual dysfunction
- → Male erectile dysfunction
- → Libido enhancement
§ Reported Side Effects
- · Nausea (common)
- · Flushing
- · Headache
- · Injection site reactions
- · Transient hypertension
§ Research, Experiences & Trends
Mechanism of Action
Activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, modulating neural pathways involved in sexual arousal and desire. Derived from Melanotan II but engineered specifically for sexual function.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Nausea (common)
- • Flushing
- • Headache
- • Injection site reactions
- • Transient hypertension